Highbridge Capital Discloses New Passive Stake in Capricor Therapeutics

TL;DR

**Highbridge Capital just bought into Capricor Therapeutics, signaling institutional interest.**

AI Summary

Highbridge Capital Management LLC, a New York-based investment firm, has reported a new passive ownership stake in Capricor Therapeutics, Inc. (NASDAQ: CAPR) as of December 31, 2023. This filing indicates Highbridge now holds a significant, though unspecified, percentage of Capricor's Common Stock, par value $0.001 per share. This matters to investors because it signals that a large institutional investor sees value in Capricor, potentially boosting confidence and attracting further investment, or it could simply be a routine disclosure of a new position.

Why It Matters

The disclosure of a new institutional investor like Highbridge Capital Management LLC can signal market confidence in Capricor Therapeutics, potentially influencing other investors and the stock's performance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a passive investment, indicating no immediate risk or major change in company control.

Analyst Insight

A smart investor would view this as a positive signal, indicating institutional validation of Capricor Therapeutics. While not a guarantee of future performance, it suggests that a sophisticated investor sees value. It might be worth researching Capricor's fundamentals and recent news to understand Highbridge's rationale.

Key Numbers

• $0.001 — Par Value per Share (The stated par value of Capricor Therapeutics' Common Stock.)
• December 31, 2023 — Event Date (The date as of which Highbridge Capital Management LLC's ownership stake was established, triggering this filing.)

Key Players & Entities

• Highbridge Capital Management LLC (company) — reporting person, institutional investor
• Capricor Therapeutics, Inc. (company) — subject company, issuer of securities
• December 31, 2023 (date) — date of event requiring the filing
• $0.001 (dollar_amount) — par value per share of Common Stock
• 14070B309 (other) — CUSIP Number for Capricor Therapeutics Common Stock

Forward-Looking Statements

• Capricor Therapeutics' stock price may see a short-term positive reaction due to increased institutional interest. (Capricor Therapeutics, Inc.) — medium confidence, target: Q1 2024
• Highbridge Capital Management LLC will maintain its passive investment stance in Capricor Therapeutics. (Highbridge Capital Management LLC) — high confidence, target: End of 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0662sc13g.htm (SC 13G) — 48KB
• 0000902664-24-001223.txt ( ) — 50KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Capricor Therapeutics, Inc. (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 10865 Road to the Cure, Suite 150, San Diego, California 92121.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by Highbridge Capital Management, LLC (" Highbridge " or the " Reporting Person "), a Delaware limited liability company and the investment adviser to certain funds and accounts (the " Highbridge Funds "), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

(c)

Item 2(c). CITIZENSHIP: Highbridge is a Delaware limited liability company.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001 per share (the " Common Stock ").

(e)

Item 2(e). CUSIP NUMBER: 14070B309 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act, (b) ¨ Bank as defined in Section 3(a)(6) of the Act, (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act, CUSIP No. 14070B309 13G Page 4 of 6 Pages (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940, (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E), (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d1(b)(1)(ii)(F), (g) ¨ Parent Holding Company or control person in accordance with Rule 13d1(b)(1)(ii)(G), (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act, (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference. The percentage set forth herein is calculated based upon 30,792,869 shares of Common Stock outstanding as of November 13, 2023, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 14, 2023. Item 5. Not applicable. Item 6. See Item 2. The Highbridge Funds have the right to receive or

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. DATED: February 7, 2024 HIGHBRIDGE CAPITAL MANAGEMENT, LLC By: /s/ Kirk Rule Name: Kirk Rule Title: Executive Director

View Full Filing

View this SC 13G filing on SEC EDGAR